Recs

1

Will These 3 Health-Care Doubles Keep Running?

By | More Articles
May 30, 2012 | Comments (0)

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

In this series, David takes a look at three health-care stocks that have doubled and examines whether they can keep it going for the rest of the year. Today's edition features Pharmacyclics, with BTK inhibitor ibrutinib, Affymax, which recently received approval for Omontys, and the ongoing march of XOMA's 052 drug candidate through clinical trials. Can these stocks keep running? Watch and find out.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson and The Motley Fool own shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 1899046, ~/Articles/ArticleHandler.aspx, 5/24/2013 8:22:10 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,303.10 8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
NASD 3,459.14 -0.28 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2013 4:00 PM
XOMA $4.09 Down -0.04 -0.97%
XOMA Limited CAPS Rating: *
PCYC $85.61 Up +0.01 +0.01%
PHARMACYCLICS, INC… CAPS Rating: *
AFFY $1.39 Down -0.01 -0.71%
Affymax, Inc. CAPS Rating: *
JNJ $86.82 Down -0.39 -0.45%
Johnson & Johnson CAPS Rating: *****
AMGN $105.91 Up +0.29 +0.27%
Amgen, Inc. CAPS Rating: ****

Advertisement